You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

476 Results
Document
New
Jan 2025
Document
New
Jan 2025
The Radiation Treatment Program ensures timely access to safe, evidence-based, high-quality radiation treatment. To improve patient experience and...
Drug
Other Name(s): Imfinzi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Sprycel®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Firmagon®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Inqovi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Jemperli
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daSATinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    degarelix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
degarelix
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025

Pages